You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康恩貝(600572.SH):控股子公司擬掛牌轉讓迪耳藥業25%股權
格隆匯 11-29 17:11

格隆匯11月29日丨康恩貝(600572.SH)公佈,為聚焦發展公司中藥大健康產業核心業務,及時處置低效資產、回籠資金,公司控股子公司浙江金華康恩貝生物製藥有限公司(以下簡稱:金華康恩貝)擬通過浙江產權交易所公開掛牌轉讓所持有的浙江迪耳藥業有限公司(以下簡稱:迪耳藥業)25%股權。

根據截至評估基準日2020年12月31日的評估結果,迪耳藥業股東全部權益評估價值為158,988,914.30元人民幣,金華康恩貝持有迪耳藥業25%股權的評估價值為39,747,228.58元。綜合考慮資產評估結果及市場和迪耳藥業等情況,經公司十屆董事會第十五次(臨時)會議審議通過,同意金華康恩貝以不低於39,747,229元的掛牌價在浙江產權交易所掛牌轉讓迪耳藥業25%股權,同意授權公司經營管理層根據《企業國有資產交易監督管理辦法》相關規定和公司有關制度決定和辦理包括但不限於上述股權轉讓本次和後續在產權交易所公開掛牌所需的有關事宜,根據公開掛牌成交情況簽署標的股權轉讓交易的有關合同(協議)以及相關文件,及辦理完成此項交易有關的各項手續等。此次股權轉讓交易完成後,金華康恩貝將不再持有迪耳藥業股權。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account